1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Vivanza Biosciences Ltd.

Vivanza Biosciences Ltd.

BBSE:VIVANZA
1.60
INR
0.00
(0.00%)
0.12EPS
15.72P/E
72.80MMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
- -
- -
- -
1.09
1.61
0.66
2.41
2.47
2.6
4.45
6.96
1.86
28.98
29.63
Basic EPS, GAAP
-0.01
-0.01
-0.02
-0.1
0.05
-0.11
-0.05
0.02
0.08
0.15
0.14
-0.17
0.1
0.12
Free Cash Flow per Basic Share
-0.01
-0.01
-0.01
-0.65
-0.02
0.22
0.74
0.04
0.62
-0.24
0.5
-0.63
-0.68
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.06
0.04
0.13
0.88
0.93
0.82
0.77
0.79
0.87
1.02
1.16
0.99
1.09
- -
Tangible Book Value per Share
0.06
0.04
0.13
0.47
0.52
0.41
0.36
0.38
0.46
0.61
0.75
0.58
0.68
- -
Basic Weighted Avg Shares
38
38
32
32
40
40
40
40
40
40
40
40
40
39
Sales/Revenue/Turnover
- -
- -
- -
35
64
27
96
99
104
178
278
74
1,159
1,163
Operating Margin (%)
- -
- -
- -
-8.56
9.35
-0.75
-3.47
1.31
0.8
4.09
3.94
-4.41
0.62
0.41
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-1
-1
-1
-3
2
-4
-2
1
3
6
5
-7
4
5
Effective Tax Rate (%)
- -
- -
- -
- -
12.05
- -
- -
38.99
0.12
16.48
21.27
- -
27.48
28.94
Profit Margin (%)
- -
- -
- -
-8.96
3.19
-16.58
-2.14
0.76
3.2
3.36
1.97
-9.08
0.34
0.39
Working Capital
-3
-4
-6
8
12
4
1
-3
30
26
36
32
22
- -
LT Debt
- -
- -
- -
4
6
6
2
- -
26
14
27
33
9
- -
Total Equity
2
2
- -
35
37
33
31
32
35
41
46
40
44
- -
Return on Invested Capital (%)
- -
- -
- -
- -
11.18
- -
- -
1.62
0.75
5.44
7.48
- -
4.23
- -
Return on Capital (%)
- -
- -
- -
- -
10.93
- -
- -
10.32
11.79
8.99
7.97
- -
4.39
- -
Return on Common Equity (%)
-21.78
-27.33
-63.16
-17.54
5.66
-12.56
-6.46
2.41
10.01
15.78
12.54
-15.67
9.48
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
93
- -
LT Borrowings
- -
9
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
40
40
40
Market Capitalization
88
70
73

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
191
- -
Cash, Cash Equivalents & STI
- -
1
- -
Accounts Receivable, Net
- -
124
- -
Inventories
- -
36
- -
Total Current Liabilities
- -
169
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
93
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
1,410.29%
7.3%
9.95%
Free Cash Flow
402.34%
132.65%
7.83%
Net Income, GAAP
-22.29%
6.3%
-158.51%
Sales/Revenue/Turnover
- -
304.17%
1,461.44%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
24
30
15
5
74
2026
89
554
453
64
1,159
2027
93
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.07
- -
0.01
-0.25
-0.17
2026
0.02
0.14
0.05
-0.11
0.1
2027
0.04
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Jaynedra A. Mehta
Full Time Employees
6
Sector
Health technology
Industry
Pharmaceuticals: major
Address
403, Sarthik-II Ahmedabad GU India 380054
IPO Date
Feb 21, 1995
Website
vivanzabiosciences.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Vivanza Biosciences Limited Vivanza Biosciences Limited engages in the research, development, manufacture, and distribution of pharmaceutical products primarily in India. The company offers a range of core products and services including latex surgical gloves, latex examination gloves, latex-free gloves, other surgical products, injectable pharmaceuticals such as Doxapram HCl Injection USP, Morphine Sulfate Injection USP, Leucovorin Calcium for Injection, Lorazepam Injection USP, Pantoprazole Sodium for Injection, and Paricalcitol Injection, as well as generic and novel pharmaceuticals, oral drug delivery systems, complex oral and topical dose forms, highly potent compounds, modified release products, veterinary medicines, pharmaceutical injections, tablets, food preservatives, and skin care products; it also provides finished product manufacturing and delivery services. Vivanza Biosciences Limited operates from its headquarters at 403, Sarthik II, Opposite Rajpath Club, S.G. Highway, Ahmedabad, Gujarat 380054, India, with additional facilities in areas such as Village Visanvel, Taluka Malya Hatina, District Junagadh; the company was incorporated in 1982. In recent developments, the company appointed CS Chaitra Arora as its new Company Secretary and Compliance Officer effective from a board meeting on November 11, 2025, replacing CS Siddhi Shah who resigned, and proposed a major business expansion into the manufacturing, processing, production, and distribution of plastic polymer films, plastic bags and sacks from various polymers, paper bags for packaging, and flexible packaging materials for industrial and consumer applications, subject to shareholder approval via postal ballot with results expected by December 18, 2025; it also reported Q2 FY2026 revenue of Rs. 373.18 lacs and profit before tax of Rs. 46.21 lacs to Rs. 48.06 lacs for the quarter ended September 30, 2025. The company targets healthcare providers, medical practitioners, patients, and industrial clients across pharmaceuticals, biosciences, and emerging packaging sectors, with a focus on domestic markets in India.